A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

NCT01075282 · Completed

Last updated 2026-05-28

This clinical trial tested a new treatment in adults with type 2 diabetes to see how it affects blood sugar levels over one year.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 810 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-02 · est. completion 2012-11

Where 78 sites · Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, France, Greece, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan

What this study is testing ClinicalTrials.gov NCT01075282 ↗

Description as written by the study sponsor.

The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.

Treatments tested

Insulin Glargine Drug
LY2189265 also known as Dulaglutide Drug
Metformin Drug
Glimepiride Drug

Main thing measured	Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01075282 ↗